HCW Biologics (NASDAQ:HCWB) Trading Up 9.1% – What’s Next?

Shares of HCW Biologics Inc. (NASDAQ:HCWB) were up 9.1% during mid-day trading on Friday . The stock traded as high as $10.00 and last traded at $8.95. Approximately 350,959 shares changed hands during mid-day trading, an increase of 37% from the average daily volume of 256,073 shares. The stock had previously closed at $8.20.

HCW Biologics Stock Performance

The stock has a market cap of $10.05 million, a price-to-earnings ratio of -8.95 and a beta of 0.85. The company has a 50-day moving average of $9.42 and a 200-day moving average of $14.43.

HCW Biologics (NASDAQ:HCWB) last released its earnings results on Thursday, May 15th. The company reported ($0.05) earnings per share (EPS) for the quarter. HCW Biologics had a negative return on equity of 2,516.84% and a negative net margin of 1,067.82%.

Insiders Place Their Bets

In other HCW Biologics news, CFO Rebecca Byam bought 8,462 shares of the company’s stock in a transaction on Thursday, May 8th. The shares were bought at an average price of $26.00 per share, for a total transaction of $220,012.00. Following the transaction, the chief financial officer now owns 43,010 shares of the company’s stock, valued at approximately $1,118,260. This trade represents a 24.49% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Lee Flowers bought 962 shares of the company’s stock in a transaction on Thursday, May 8th. The shares were acquired at an average price of $26.00 per share, for a total transaction of $25,012.00. Following the transaction, the senior vice president now directly owns 5,720 shares in the company, valued at $148,720. This trade represents a 20.22% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 11,732 shares of company stock worth $305,032. Company insiders own 49.90% of the company’s stock.

About HCW Biologics

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.